These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 706890)

  • 21. [Role of immunologic activity of host in radiotherapy].
    Tsuchiya T
    Gan No Rinsho; 1983 Oct; 29(13):1499-505. PubMed ID: 6608014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Natural killer activity of splenocytes of C3HA mice in the early period after transplantation of hepatoma 22a cells].
    Filatova NA; Malygin AM; Pleskach VA; Fel' VIa
    Eksp Onkol; 1987; 9(6):52-5. PubMed ID: 3436291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of spleen macrophage activation in inhibiting the metastasis of transplantable tumors].
    Arkhipov SA; Iunker VM; Gruntenko EV
    Vopr Onkol; 1985; 31(9):77-84. PubMed ID: 2996226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ultradian fluctuations in the natural antitumor resistance of mice undergoing transplantation and chemical carcinogenesis].
    Suslov AP; Riabykh TP; Slavina EG; Kasatkina NN; Leĭpunskaia IL
    Tsitologiia; 1987 Jan; 29(1):79-85. PubMed ID: 3564161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of impaired T cell functions in tumor-bearing mice by the administration of interleukin 1.
    Yamashita U; Shirakawa F
    Jpn J Cancer Res; 1987 Mar; 78(3):270-8. PubMed ID: 3106283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cellular immunity in an experimental ascites tumor: tumor immunostimulation mediated by splenic lymphocytic cells].
    García Villarrubia V; Moreno Koch MC
    Rev Esp Oncol; 1981; 28(2):169-94. PubMed ID: 7052966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of effector cells mediating antitumor activity in spleen cells of tumor-bearing mice.
    Fuyama S; Yamamoto H; Arai S
    Cancer Res; 1985 Sep; 45(9):4103-8. PubMed ID: 3875404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H; Takai Y; Sakamoto K; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2187-91. PubMed ID: 3874911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide.
    Tzai TS; Lin JS; Chow NH
    J Surg Res; 1996 Oct; 65(2):139-44. PubMed ID: 8903460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The regulation of splenocyte natural killer activity in C3HA mice in the early period after hepatoma 22a transplantation].
    Filatova NA; Malygin AM; Pleskach VA; Fel' VIa
    Eksp Onkol; 1989; 11(2):42-5. PubMed ID: 2786801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ambiguous action of splenocytes from tumor-bearing mice on the formation of metastases in the lungs of mice in an adaptive transfer system].
    Iunker VM; Arkhipov SA; Gruntenko EV
    Biull Eksp Biol Med; 1984 Nov; 98(11):598-600. PubMed ID: 6509179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antitumor effect of the extract of birch bark and its influence to the immune function].
    Han S; Li Z; Li Y; Zhong R
    Zhong Yao Cai; 2000 Jun; 23(6):343-5. PubMed ID: 12575089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Characteristics of the morphofunctional changes in the liver of C3HA mice due to immunization with a homogenate of normal syngeneic liver].
    Medvedeva ND; Chernysheva MD; Pogodina ON; Fel' VIa
    Tsitologiia; 1987 Feb; 29(2):239-43. PubMed ID: 3576705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characteristics in antitumor effects of organic silicon related compounds].
    Fukushima K
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2173-81. PubMed ID: 2544147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
    Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
    J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.